Authors

Molecular diagnostic practice in prostate and bladder cancers

"Liquid biopsy analysis provides a noninvasive and facile tool for early detection, diagnosis, and recurrence surveillance of urological cancer," writes Jim Lu, MD, PhD.

Strategies to mitigate impact of intravenous ICM shortage

"The global shortage of ICM has necessitated rapid adaptation of workflows and clinical pathways, which are particularly important for practicing urologists who are evaluating patients for hematuria," write Yair Lotan, MD, and colleagues.

Money Matters: Informing your perspective on the bear market

No matter what your age or risk tolerance, investing is a lot easier and likely more successful if your perspective is informed by market history.

Expert explains challenges of telehealth

Although much of the discourse around telehealth rightfully focuses on its benefits, the potential drawbacks and limitations are often glossed over, particularly around provider burden.

Ensuring operational continuity is critical with healthcare data breaches

With healthcare data breaches approaching a boiling point, care providers need to adopt an approach that prioritizes operational continuity.

Setting the Course for More Options and More Choice in Prostate Cancer Care

Managing aging and frailty in the urologic cancer population

Increasing numbers of older patients with cancer necessitates adoption of an age-friendly approach to cancer care.

Cretostimogene grenadenorepvec made available through expanded access program

Cretostimogene grenadenorepvec is an intravesical oncolytic immunotherapy currently under investigation in phase 3 trials.

Making Sense of the Reintervention Rate for BPH

Investigational HIF-2α inhibitor shows activity, safety in advanced clear cell RCC

This monotherapy was safe for all doses and dosing schedules observed in the study and daily doses showed initial antitumor activity.

Update on advanced imaging in prostate cancer

Advances allow for more accurate detection of metastatic disease.

Practical Considerations for the Treatment of Patients With Metastatic Castration-Sensitive Prostate Cancer

The emotional toll of surgical complications on urologic surgeons

"It is important as a field that we recognize the potential emotional impact of surgical adverse events," writes Amy N. Luckenbaugh, MD.

Lymph nodes in bladder cancer: Past, present, and future

"Based on the LEA and S1011 trials, it has become clear that patients do not benefit from an extended LND, and a standard bilateral pelvic LND is the standard of care," write Amir Soltani-Tehrani, MD, and Kamal S. Pohar, MD.

PARP inhibitors: Treating mCRPC from a genetic basis

Treatments provide a targeted therapeutic strategy for metastatic castration-resistant prostate cancer.

How to implement an ERAS pathway in your urology practice

Program encompasses patient counseling, anesthetic planning, and early mobilization.

AACU 2024 Advocacy Summit & Annual Meeting

This year, the AACU 2024 Advocacy Summit & Annual Meeting will focus on the intersection of health policy and clinical practice, as well as the impact of current state and national legislative trends on urology.

Distinguishing between malignant and benign renal masses

"Augmented biopsy-based and noninvasive options are available to reduce benign resection rates of renal tumors with the consideration of PEER and 99mTc-sestamibi SPECT/CT," writes Hiten D. Patel, MD, MPH.

Diagnostic stewardship for urinary tract infection: A snapshot of the expert guidance

Urinary tract infections (UTIs) are among the most common human infections. But the urine culture, the cornerstone for laboratory diagnosis of UTI, is imperfect.

How to implement an ERAS pathway in your urology practice

Program encompasses patient counseling, anesthetic planning, and early mobilization.

The American Board of Urology: Considerations for the urologist in career transitions

"The ABU continues to reevaluate all policies related to diplomates. As medical practice continues to evolve in United States, and these changes affect the practitioners of medicine, likely further changes will be necessary in board certification procedures," writes Roger Dmochowski, MD, MA (Conflict Management and Resolution), MMHC, FACS.

UCI receives renewal as Orange County’s only federally designated comprehensive cancer center

The National Cancer Institute has again recognized the UCI Chao Family Comprehensive Cancer Center as one of the nation’s top cancer centers, renewing its “comprehensive” designation

Legislative efforts to eliminate barriers to prostate cancer screening ramp up

"Our success depends on your assertive action and membership in organizations serving our specialty—the AACU in particular—as well as your state medical association," writes William C. Reha, MD, MBA.

2024 Urology Times pipeline report

Catch up on all the notable drug and device approvals in urology over the past year.

MIPS success: What specialists need to know

"Specialty providers can take three steps now to succeed with MIPS while prioritizing caring for their patients," writes Wayne Singer.

Recognizing hereditary syndromes in renal cell carcinoma

Patients may require specific diagnostic, surveillance, and therapeutic management.

EBRT not linked to increased hematological toxicity for mCRPC treated with Ra-233

Drug-related hematological treatment-emergent adverse events were proportionately similar between the EBRT cohort and the those who did not receive EBRT to the bone.

PARP inhibitors: Treating mCRPC from a genetic basis

Treatments provide a targeted therapeutic strategy for metastatic castration-resistant prostate cancer.